PIPELINE
Platform Expansion: Turning the Undruggable into the Druggable
One delivery platform, engineered for many diseases. Our most advanced program targets KRAS G12V in pancreatic cancer, reaching a driver with no FDA-approved targeted therapy.
Malaria and spinal muscular atrophy programs are advancing behind it, built on the same delivery mechanism.
KRAS G12V PROGRAM
A Program Challenged by
One of Oncology's Hardest Targets
KRAS is one of the most frequently mutated oncogenes, driving tumor initiation, progression and therapeutic resistance across pancreatic, colorectal and lung cancers.
Mutant KRAS proteins remain among oncology's most challenging intracellular targets due to their intracellular localization, structural complexity and central role in multiple signaling and metabolic pathways.
KRAS G12V is one of the most aggressive and treatment-resistant KRAS variants, representing a significant unmet clinical need.
Its exceptional biological importance and therapeutic difficulty make KRAS G12V an ideal proof-of-concept target for demonstrating the capabilities of the COMED Hooks intracellular delivery platform.